Network meta-analysis of 47 RCTs (75,978 patients) with HFrEF feeding a UK cost-effectiveness model: quadruple therapy (ARNI + β-blocker + MRA + SGLT2i) gave most benefit and was most cost-effective (12.31 QALYs); consistent in Sweden and US.
Meta-analysisn = 75,978
Laborante et al. A NETwork meta-analysis with COST-effectiveness evaluation of pharmacological treatments for heart failure with reduced ejection fraction: NET-COST-HFrEF